Abstract
Goal Smartphone and wearable devices may act as powerful tools to remotely monitor physical function in people with neurodegenerative and autoimmune diseases from out-of-clinic environments. Detection of progression onset or worsening of symptoms is especially important in people living with multiple sclerosis (PwMS) in order to enable optimally adapted therapeutic strategies. MS is a disease whose symptoms typically follow subtle and fluctuating disease courses, patient-to-patient, and over time. Current in-clinic assessments are often too infrequently administered to reflect longitudinal changes in MS impairment that impact daily life. This work, therefore, explores how smartphones can administer daily two-minute walking assessments to monitor PwMS physical function at home.
Methods Remotely collected smartphone inertial sensor data was transformed through state-of-the-art Deep Convolutional Neural Networks, to estimate a participant’s daily ambulatory-related disease severity, longitudinally over a 24-week study.
Results This study demonstrated that smartphone-based ambulatory severity outcomes could accurately estimate MS level of disability, as measured by the EDSS score (r2: 0.56,p <0.001). Furthermore, longitudinal severity outcomes were shown to accurately reflect individual participants’ level of disability over the study duration.
Conclusion Smartphone-based assessments, that can be performed by patients from their home environments, could greatly augment standard in-clinic outcomes for neurodegenerative diseases. The ability to understand the impact of disease on daily-life between clinical visits, through objective digital outcomes, paves the way forward to better measure and identify signs of disease progression that may be occurring out-of-clinic, to monitor how different patients respond to various treatments, and to ultimately enable the development of better, and more personalised care.
Competing Interest Statement
During the completion of this work, A. P. Creagh was a Ph.D. student at the University of Oxford and acknowledges the support of F. Hoffmann-La Roche Ltd.; F. Dondelinger and F. Lipsmeier are employees of F. Hoffmann-La Roche Ltd; M. Lindemann is a consultant for F. Hoffmann-La Roche Ltd. via Inovigate; M. De Vos has nothing to disclose.
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT02952911
Funding Statement
This study was sponsored by F. Hoffmann-La Roche Ltd. This research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). This research also received funding from the Flemish Government under the "Onderzoeksprogramma Artificiele Intelligentie (AI) Vlaanderen" programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided informed consent, and the ethical approval was obtained from ethics committee of the Hospital Universitari Vall d'Hebron, Barcelona, Spain and the institutional review board of the University of California San Francisco, San Francisco, CA, USA, prior to study initiation. The study was registered on clinicaltrials.gov (NCT02952911).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
frank.dondelinger{at}roche.com
florian.lipsmeier{at}roche.com
michael.lindemann{at}roche.com
maarten.devos{at}kuleuven.be
↵† These authors jointly supervised;
Data Availability
Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
